The goal of our research was to compare the pharmacokinetics and evaluate the bioequivalence of two brands of cephradine 500 mg capsules in 24 normal Korean volunteers. The plasma samples were acquired at 13 time points for 8 h after administration. The concentrations of cephradine in human plasma were measured by a high-performance liquid chromatography (HPLC). Isocratic mobile phase which consisted of acetonitrile, methanol, and 20 mM potassium phosphate (15/5/80, v/v/v, pH 3.48) was used to separate the analytical column cosmosil cholester (250 × 4.6 mm, 3 µm). Analytes were detected in ultraviolet (260 nm). The novel analytical method was described as simple sample preparation, a short retention time (less than 6 min) and making it suitable for use in clinical trials. Pharmacokinetic parameters, such as ) were determined for the reference and test drugs in plasma. Pharmacokinetic parameters with a 90% confidence interval were 87% -95% for AUC 0-t and 91% -115% for C max . They were satisfied within the bioequivalence range 80% -125% of the KFDA guidelines. Therefore, our HPLC method was well applied in a bioequivalence and pharmacokinetic study of two formulations in normal subjects.
Introduction

Cephradine ((6R
no}-3-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid) is a first generation cephalosporin antibiotic. It has broad spectrum antibacterial activity against gram-positive and gram-negative microorganisms and acts through inhibiting bacterial cell wall synthesis. Cephradine is used to treat upper respiratory infections, ear infections, skin infections, and urinary tract infections. It is rapidly absorbed from the gastrointestinal tract and has low plasma protein binding (6% -20%) [1] . It is excreted approximately 90% of the drug which is unchanged by the kidney within 6 h administration [2] . A daily therapeutic dose of cephradine is 250 -500 mg, and after oral administration of 500 mg of cephradine the maximal plasma concentration (C max ) is 15.67 ± 4.21 μg/mL and the time to maximal plasma concentration (T max ) is about 1 h [3] .
Several analytical methods have been reported to measure cephradine in biological fluids. These methods include spectrophotometry [4] [5] [6] , spectrofluorimetry [7] [8], luminescence [9] [10], capillary electrophoresis [11] , and bioassays [1] [2] [12] [13] [14] . The previous methods often lack sufficient sensitivity and specificity to measure low cephradine concentrations in plasma. Recent studies have used high-performance liquid chromatography (HPLC) [15] - [22] and liquid chromatography tandem mass spectrometry (LC-MS/MS) [23] [24] in order to increase the sensitivity to detect cephradine in biological materials. However, these methods have disadvantages as follows. HPLC methods take a long time and LC-MS/MS methods require the startup costs and highly skilled human resource to perform the assays and manage the instrument. The comparative details of literature are provided in Table 1 .
Since the Drug Price Competition and Patent Term Restoration Act were implemented in 1984, the US Food and Drug Administration (FDA) have established bioavailability and bioequivalence requirements for generic substitution [13] [25] [26] . According to the Act, the goal of clinical bioavailability studies is to compare certain pharmacokinetic (PK) parameters of the test and reference products. The current bioequivalence test requires, to declare bioequivalence, the population mean differences in the extent (area under the curve (AUC)) and rate of absorption (C max ) between the test and reference formulations do not exceed 20% [25] . Therefore, our purpose of research was to develop a fast, convenient, and efficient method to analyze biological cephradine levels and use it to measure cephradine concentrations in human plasma samples in the bioequivalence and pharmacokinetic test of 2 brands of cephradine capsules (500 mg) in 24 normal Korean subjects.
Furthermore, we performed a comparison of basic PK parameters such as 
Materials and Methods
Chemical and Reagents
Cephradine and ofloxacin (Internal Standard (IS)) were purchased from Sig- 
Instrumentation and Analytical Conditions
The 
Preparation of Standards and Plasma Samples
Primary stock solutions of cephradine and IS were prepared in 50% aqueous Following centrifugation, the supernatant was transferred to an autosampler vial and an aliquot (50 μL) was injected into the HPLC system.
Assay Validation
The assay was validated according to the FDA guidance on validation of bioanalytical methods [28] [29] . Linearity was determined with a linear least-squares regression with 1/x 2 weighting, performed on the peak area ratios of cephradine and IS versus the cephradine concentrations of the seven blank plasma stan- 
Bioequivalence and Pharmacokinetic Test in Normal Subjects
To evaluate the applicability of this method, a randomized, two-period, and crossover design was used to study the pharmacokinetics and bioequivalence of two types of cephradine in 24 normal Korean subjects.
The study was performed according to the World Medical Association Declaration of Helsinki (1997) for biomedical research involving human subjects in 2007 [30] and protocol was confirmed by the Institutional Review Board of Hanyang University Medical Center [31] - [38] . This study design and number of subjects were properly decided to achieve sufficient statistical power to demonstrate BE test according to the Korean FDA Guidelines [39] . The candidate subjects were recruited by internet and paper notice. Enrolling subjects were selected to depend on inclusion criteria of the Korean FDA Guidelines [39] . Twenty-four subjects aged between 19 -25 years (21.8 ± 2.4 years), with heights between 169 -180 cm (174.0 ± 3.6 cm) and body weights between 58 -83 kg (67.3 ± 6.4 kg) were selected. The subjects were non-alcoholics and disease-free and were assessed as being healthy by a clinical evaluation, including a physical examination and routine clinical laboratory tests including a pregnancy test. One capsule of cephradine (500 mg) was given randomly to 24 healthy subjects. Participants had not taken other medication (including OTC regimens) for two weeks before the study, and refrained from taking other medication during the study period, including the washout period. During each study period, the volunteers were hospitalized at Hanyang University Medical Center at 5:00 pm. and had supper before 8:00 pm. After an overnight fast, they were administered with a test or reference formulation along with 240 mL water at 7:30 am. Food and beverage were not permitted until 4 h after dose. A regular lunch was provided at 4 h after dose and the vital signs of subjects were recorded at times before and after dose. Blood Samples (9 mL) were collected through a catheter with heparin-containing tubes from a suitable antecubital vein before and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, and 8 h after dose. The samples were centrifuged at 3000 rpm for 10 min at room temperature and the plasma was stored at −70˚C until analyzed [34] [35] [36] [37] [38] . The C max and T max were determined from each subject's plasma level of cephradine versus time plots. Other PK parameters were analyzed and calculated to using PK Solutions software as non-compartmental in the body was calculated as AUMC/AUC, with λ z being the Ke [40] . To assess bioequivalence of the test and reference drugs, AUC 0-t and C max were considered to be the primary variables, and a 2-way ANOVA for the crossover-randomized design was used to estimate the effect of types, term, sequence, and subjects on these parameters [41] . Differences between 2 related parameters were regarded statistically significant at p < 0.05. The 90% confidence intervals (CI) of the geometric means for the individual test/reference ratios (T/R) for AUC 0-t , and C max were calculated, in order to evaluate bioequivalence of the 2 types. The parametric 90% CIs for the ratios in the 80% -125% range suggested by the Korean Food and Drug Administration (KFDA) were calculated using parametric methods for log-transformed data [41] .
Results and Discussion
Analysis
The molecular structures of cephradine and ofloxacin (IS) were indicated in (Figure 2(a) ). Our HPLC method was showed short run time (7 min) than previous methods (10 -28 min) [15] - [22] (Table 1) .
Method Validation and Linearity of Calibration
A calibration curve was constructed from the peak area ratios of cephradine against IS by using a double-blank sample (plasma sample without cephradine . Intra-and inter-day precision and accuracy were determined by analyzing QC samples against the calibration curve, on the same day (n = 5) and on different days (n = 5). As indicated in Table 2 , intra-and inter-day precisions were 3.27% -4.75% and 4.56% -6.22%, respectively, and intra-and inter-day accuracies were 99.71% -105.65 % and 97.48% -99.86 %, respectively. The LLOQ was decided to accept the 0.3 μg/mL under the analytical conditions of the precision and accuracy less than 20% [28] . Therefore, our research was yielded sufficiently the analytical method for pharmacokinetics and bioequivalence studies.
Pharmacokinetics and Bioequivalence
The proposed method was applied to the determination of cephradine in plasma samples for the purpose of establishing the pharmacokinetic and bioequivalence study of 500 mg cephradine formulations in 24 healthy Korean volunteers [42] . The demographic characteristics for each of the healthy volunteers studied are given in Table 3 . There were 22 men and 2 women. Subjects were randomly assigned to receive the reference or test formulation. The PK parameters for the reference and test drug obtained were described as follows. The first sampling time of 24 subjects were measurable at 0.25 h after oral administration of cephradine. The profiles of the plasma cephradine concentration vs time were shown in Figure 3 . Even though the bioavailability of orally administered cephradine is characterized by considerable individual variation, plasma concentration-time profiles of the two formulations were similar patterns.
The PK parameters of cephradine were shown in Table 4 and (Table 5) , the PK data of cephradine after oral administration were rapid with 0.80 -1.25 h of T max , 0.61 -0.95 h of half-life (T 1/2 ), 12.11 -17.7 μg/mL of C max , and 23.14 -27.52 μg•h/mL of AUC ∞ under similar conditions. The mean T max values under different conditions of cephradine 1 kg and 250 mg were 1.12 ± 0.24 h and 0.76 ± 0.12 h, respectively [2] [22] . Our results agreed well with these parameter values. Therefore, it means that there were no difference between Korean subject and the other races. = the half-life of elimination, λ z (k e ) = the elimination rate constant, CL= clearance. 
Conclusion
We developed a fast HPLC method to measure cephradine in human plasma. It was based on removing protein by precipitation, and used a high resolution column and a fast isocratic flow rate. This method had similar precision and accuracy to previous methods, whereas, it had indicated more short analysis times (cephradine [4. 
